NCT06613516 - Effect of Capivasertib on ctDNA in ER Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2027

Conditions

Breast CancerOestrogen Receptor Positive Breast Cancer

Interventions

DRUG

Capivasertib

Capivasertib is a selective inhibitor of the kinase activity of the serine/threonine Akt/PKB pathway that may potentially provide clinical benefit over a range of therapeutic indications. Capivasertib comes in capsule form in two forms; 160mg or 200mg

Trial Locations (1)

Unknown

Imperial College Healthcare Trust, London